Explore published findings of medical trials and real-world evidence.
This page includes links to Novo Nordisk-sponsored trials and observational research published in peer reviewed journals. The list of publications below is sorted by product and limited to products that have been approved for use.
Please note that publications may contain information about doses, delivery devices, uses, formulations and/or populations that differs from FDA-required labeling.
Novo Nordisk does not suggest or recommend the use of its products in any manner other than as described in their FDA-required labeling, which is findable under each product below.
Products are listed in order of the most recent FDA approval, with the most recent shown first.
(semaglutide) injection 2.4 mg, 7.2 mg, tablets 25mg | Full Prescribing Information
Published Date: November 13, 2025
Once-weekly semaglutide in adolescents with obesity.
Published Date: December 15, 2022
Published Date: August 2022
Published Date: November 2020
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Published Date: September 18, 2025
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Published Date: October 2022
Semaglutide 2.4mg for the treatment of obesity: Key elements of the STEP 1-5 trials.
Published Date: June 2020
Published Date: February 2025
Published Date: October 2022
(liraglutide) injection 3 mg | Full Prescribing Information
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Published Date: May 2020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Published Date: July 2015
Retrospective descriptive analysis of a managed care population with obesity.
Published Date: January 2022
Simulating the fiscal impact of anti-obesity medications as an obesity reduction strategy.
Published Date: January-December 2021
The relative value of anti-obesity medications compared to similar therapies.
Published Date: January 26, 2023
Find product information
Explore our portfolio of products, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Learn about accredited disease education opportunities supported by Novo Nordisk and provided by third-party organizations.